Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Zheng‐Yi Zhou"'
Autor:
Mark E. Bensink, Deborah Goldschmidt, Zheng-Yi Zhou, Kaijun Wang, Richard Lieblich, Martin C. Bunke
Publikováno v:
Kidney Medicine, Vol 6, Iss 2, Pp 100759- (2024)
Rationale & Objective: This study describes the epidemiology, characteristics, and outcomes of patients with immunoglobulin A nephropathy (IgAN)-attributed kidney failure in the US Renal Data System (USRDS) from 2008 to 2018, including health care re
Externí odkaz:
https://doaj.org/article/314bdeb7d38c4f71a0f7f4fe3d5f0fc6
Autor:
Mark E. Bensink, Deborah Goldschmidt, Zheng-Yi Zhou, Kaijun Wang, Richard Lieblich, C. Martin Bunke
Publikováno v:
Kidney Medicine, Vol 6, Iss 2, Pp 100760- (2024)
Rationale & Objective: This study describes the epidemiology, characteristics, and clinical outcomes of patients with focal segmental glomerulosclerosis (FSGS)-attributed kidney failure in the US Renal Data System (USRDS) during 2008-2018, and health
Externí odkaz:
https://doaj.org/article/4b1ded3784244132af98948074b8a9de
Autor:
Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8005-8017 (2023)
Abstract Backgound Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matc
Externí odkaz:
https://doaj.org/article/25757ea5c0d04b968bda33b211f19236
Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
Autor:
Herbert H. Loong, MBBS, FRCP, Carlos K.H. Wong, PhD, Catherine P.K. Chan, PharmD, Andrea Chang, MBA, Zheng-Yi Zhou, PhD, Wenxi Tang, MS, Meaghan Gibbs, MSc
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 3, Pp 100290- (2022)
Introduction: Upfront next-generation sequencing (NGS) in patients with metastatic NSCLC has been associated with cost savings and shorter time-to-test results in the United States. Nevertheless, this may not apply in jurisdictions where the prevalen
Externí odkaz:
https://doaj.org/article/5b08081e67694eb5ae51189526b80dfd
Autor:
Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie, Meaghan Gibbs
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Introduction Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC). This st
Externí odkaz:
https://doaj.org/article/436f8f37a082436bb28442a062ac874c
Autor:
Sikander Ailawadhi, Kejal Parikh, Safiya Abouzaid, Zhou Zhou, Wenxi Tang, Zoe Clancy, Claudia Cheung, Zheng-Yi Zhou, Jipan Xie
Publikováno v:
Blood Advances, Vol 3, Iss 20, Pp 2986-2994 (2019)
Abstract: The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and
Externí odkaz:
https://doaj.org/article/90c5d271dd444c8dbece549b8e654e15
Autor:
Zheng, Yi-Zhou, Chen, Qing-Rou, Yang, Hong-Mei, Zhao, Ji-Ao, Ren, Ling-Zhi, Wu, Ye-Qun, Long, Yong-Ling, Li, Tong-Ming, Yu, Yang
Publikováno v:
In International Journal of Biological Macromolecules March 2024 262 Part 2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Min Huang, Peter A. Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O’Shaughnessy
Publikováno v:
Advances in Therapy. 40:1153-1170
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3ef10038bd4943075dba2d66d110cdc
https://doi.org/10.1007/s12325-022-02365-1
https://doi.org/10.1007/s12325-022-02365-1
Autor:
Xiaoyan Lu, Zheng-Yi Zhou, Yiqiao Xin, Min-Jung Wang, Emma Gray, Vipul Jairath, James Oliver Lindsay
Publikováno v:
Inflammatory Bowel Diseases.
Background Where head-to-head trials are lacking, indirect comparative effectiveness can aid treatment decisions. We conducted matching-adjusted indirect comparisons of clinical outcomes with filgotinib vs recently approved comparators (vedolizumab,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::097eeac5dca2086f23a558bc4c823a1e
https://doi.org/10.1093/ibd/izad037
https://doi.org/10.1093/ibd/izad037